Osimertinib for the treatment of EGFR-mutant NSCLC in the adjuvant setting
In this MEDtalk, associate professor Timothy F. Burns presents targetable treatment options for patients with early-stage non-small cell lung cancer (NSCLC), explicitly targeting the epidermal growth factor receptor (EGFR).
